Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD140 in HR+ Breast Cancer
NCT03088527Phase 1Completed
- Sponsor
- Stemline Therapeutics
- Start
- Oct 2017
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vosilasarm in Hormone-Receptor-Positive Breast Cancer, sponsored by Stemline Therapeutics. Primary endpoints: Incidence rate of dose-limiting toxicities at 28 days, Number of adverse events related to study treatment and 1 more. Started Oct 2017; status: completed.
02
Drugs
vosilasarm
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT03088527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03088527.